IMM01-STEM
Sarcopenia / Age-related muscle decline
Phase 1/2Active
Key Facts
About Immunis
Immunis is a private, clinical-stage biotech pioneering a first-in-class, multi-active biologic approach to longevity medicine. Its core technology is a proprietary stem cell-derived secretome, a complex mixture of regenerative factors designed to address multiple pathways involved in age-related tissue decline. The company's lead program, IMM01-STEM, is in clinical development for sarcopenia and related conditions, targeting the vast and growing market for interventions that preserve muscle health and independence in aging populations. As a pre-revenue entity, Immunis is focused on advancing its clinical pipeline through investor funding and strategic partnerships.
View full company profile